22e9b9d1-ac71-43f5-8606-f9f53c6ecc08
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.500
- ESTROGEN_RESPONSE_LATE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- COAGULATION+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- MYOGENESIS+0.300
- P53_PATHWAY+0.300
- PANCREAS_BETA_CELLS+0.300
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V1-0.600
- PROTEIN_SECRETION-0.600
- DNA_REPAIR-0.500
- MITOTIC_SPINDLE-0.500
- MYC_TARGETS_V2-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- ANDROGEN_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001517_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.912 |
| 2 | SRR1429641 | GTEX | — | 0.901 |
| 3 | MDT-AP-0746 | Med | Medulloblastoma | 0.900 |
| 4 | MNG1237 | — | — | 0.897 |
| 5 | SRR1797250 | — | cohortMD2 | 0.895 |
| 6 | SRR1317494 | GTEX | — | 0.890 |
| 7 | 525b66e0-235a-4bf5-bc46-eb022d630115 | — | — | 0.889 |
| 8 | SRR1359171 | GTEX | — | 0.886 |
| 9 | SRR1476571 | GTEX | — | 0.885 |
| 10 | sclc1020_S66.txt | — | cohortA1 | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.500 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |